Endocrinology
- Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
These conditions often co-exist and can have complex interactions. The progression of kidney disease increases the risk of major adverse cardiovascular events.
- Inpatient glycemic management in noncritically ill patients: Updated guidelines
The guidelines include a role for newer diabetes technologies and nontraditional insulin and noninsulin therapies.
- Born again: The many lives of metformin
Repurposing old drugs for new indications is not a new drug-development strategy.
- Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?
The authors appraise the evidence to date for weight loss with metformin in this patient population.
- How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?
Differentiating type 1 from type 2 amiodarone-induced thyrotoxicosis requires serologic testing, color Doppler ultrasonography, and radioisotope studies, and influences the choice of treatment.
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and managementA review of the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, factors related to toxicity risk, and principles of management.
- What is the rationale for the laboratory workup for suspected pheochromocytomas and paragangliomas?
The decision to test is best guided by clinical suspicion. Test results should be interpreted with careful consideration of how the samples were collected.
- To repeat or not to repeat? Measuring bone mineral density during anti-resorptive therapy or a drug holiday
The authors present evidence for and against monitoring bone mineral density in these patients, arguing against a one-size-fits-all approach.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.